-
Acta Haematol: Serum ferritin threshold differentiates patients at higher risk of increased platelets during treatment with hypoxia-inducible factor prolyl hydroxylase domain inhibitors
Time of Update: 2022-03-05
PLT was significantly increased in the low s-ft group (*;PMultivariate analysis showed that PLT rate of change was associated with serum ferritin (s-ft) and red blood cell (RBC) counts [β coefficient; 0.
-
Clin Exp Med: Changes in Platelet Activity and Turnover Index During Immune Thrombocytopenia Treatment Response
Time of Update: 2022-03-05
No significant differences in plasma sCD40L (c), MPV (d), GC (e) or GC index (f) levelsFigure 2: Comparison of platelet count, platelet activity, and turnover markers in ITP at newly diagnosed versus refractory disease .
-
AJH: Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab - patient-reported results from the APOLLO trial
Time of Update: 2022-03-05
Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial .
Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial .
-
Ann Hematol: Fixed Dosing and Pharmacokinetic-Guided Adjusted Busulfan Dosing in Hematopoietic Stem Cell Transplant Patients with Greater Efficacy, Safety, and Cost-Effectiveness
Time of Update: 2022-03-05
The study was designed to evaluate the efficacy, safety, and long-term cost-effectiveness of fixed-dose busulfan (Bu) administration and pharmacokinetic (PK)-guided Bu-dosing adjustments in patients undergoing hematopoietic stem cell transplantation .
-
NEJM: Polatuzumab Vedotin for Treatment-naïve Diffuse Large B-Cell Lymphoma
Time of Update: 2022-03-05
2-year overall survival2-year overall survivalIn conclusion, among patients with previously untreated intermediate-to-high-risk DLBCL, patients treated with the modified pola-R-CHOP regimen had a relatively lower risk of disease progression, recurrence, and death compared with the standard R-CHOP regimen .
-
NEJM: How effective is Axicabtagene Ciloleucel as a second-line treatment for large B-cell lymphoma?
Time of Update: 2022-03-05
Axi-cel treatment significantly improved event-free survival and treatment response in patients with early-stage relapsed or refractory large B-cell lymphoma compared with standard therapy, but with expected high levels of toxicity .
-
Blood: venetoclax combined with R-EPOCH regimen in the treatment of Richter syndrome
Time of Update: 2022-03-05
This is a single-center Phase 2 clinical trial recruiting patients with Richter syndrome to receive venetoclax in combination with dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and Doxorubicin (VR-EPOCH) treatment .
-
NEJM: Comparison of Tisagenlecleucel or standard of care in aggressive B-cell lymphoma
Time of Update: 2022-03-05
lymphomaIn a study published today in the top medical journal NEJM, researchers conducted an international Phase 3 trial involving patients with aggressive lymphoma who did not respond or progressed within 12 months of first-line therapy .
-
ISLH: Identification of peripheral blood CD26+ leukemia stem cells has potential role in the rapid diagnosis of chronic myeloid leukemia
Time of Update: 2022-03-04
CD26+ events (cut off from FMO tubes) were gated and CD26+/CD34+/CD38− CMLLSCs were calculated as a percentage of total viable cellsFigure 1: Flow cytometry density contour plot showing the sequential gating strategy employed to identify CD26+ chronic myeloid leukemia (CML) leukemia stem cells (LSCs) .
-
Blood: The prognostic significance of negative minimal residual disease in multiple myeloma
Time of Update: 2022-03-04
Patients who achieved ≥CR and negative minimal residual disease had significantly longer progression-free survival compared with those who did not achieve complete remission or had positive minimal residual disease (hazard ratio [HR] 0.
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA .
-
What is abnormal lymphadenopathy?
Time of Update: 2022-03-04
Due to plasma extravasation and hemoconcentration, hemoglobin and red blood cell counts increased from the late stage of fever to the hypotensive shock period, and platelets began to decrease from the second day of illness, and atypical platelets were seen .
-
Blood: A predictive model for prognosis in children with classic Hodgkin lymphoma!
Time of Update: 2022-03-04
Classical Hodgkin lymphoma in children and adolescents has a unique disease biology different from that in adult patients, which can be used for risk stratification after diagnosis .
-
MICM-P comprehensive diagnosis is very important in the process of blood disease diagnosis and treatment!
Time of Update: 2022-03-04
Myelofibrosis (MF) refers to the pathological state in which bone marrow hematopoietic tissue is replaced by fibrous tissue, which affects hematopoietic function. It can be divided into primary myelo
-
Headache treats the head, foot pain treats the foot, stomach pain treats the stomach?
Time of Update: 2022-03-02
The patient's blood routine showed anemia, thrombocytopenia, and the proportion and absolute value of monocytes increased significantly.
Criteria, excluding other causes of mononucleosis, and because the patient's blood film showed Auer bodies, the final diagnosis should be CMML-2 .
-
J Thromb Haemost: Complications of postoperative bleeding in patients with hemophilia undergoing major orthopaedic surgery
Time of Update: 2022-03-02
Postoperative bleeding complications in patients with hemophilia undergoing major orthopedic surgery: A prospective multicenter observational study .
15654?af=ROriginal Source: Postoperative bleeding complications in patients with hemophilia undergoing major orthopedic surgery: A prospective multicenter observational study
-
LEUKEMIA: Combination of Erk1/2i and CDK4/6i in relapsed and refractory multiple myeloma
Time of Update: 2022-03-02
Despite advances in treatment, relapsed multiple myeloma (MM) remains incurable due to high relapse rates and the development of drug resistance . MM recurrence and progression are driven by the acc
-
In-hospital management of patients with thrombocytopenia caused by blood system diseases (2) - aplastic anemia
Time of Update: 2022-02-24
The standard therapy for severe AA is immunosuppressive therapy (IST) with ATG/ALG and cyclosporin A (CsA) for patients aged >35 years or aged ≤35 years without HLA-identical sibling donors; For severe AA patients aged ≤35 years with HLA-identical sibling donors, if there is no active infection and bleeding, HLA-identical sibling donors are the first choice for hematopoietic stem cell transplantation .
-
Editas, a company founded by Zhang Feng, initiates a clinical trial of CRISPR-Cas12a gene editing for the treatment of β-thalassemia
Time of Update: 2022-02-24
Recently, Editas Medicine, founded by Professor Feng Zhang, one of the founders of CRISPR gene editing, announced that its IND application for EDIT-301, a gene editing therapy for the treatment of transfusion-dependent beta-thalassemia, has been approved by the FDA and will be launched in 20221 /Phase 2 clinical trial to evaluate the safety, tolerability and preliminary efficacy of EDIT-301 in the treatment of transfusion-dependent beta-thalassemia .
-
ASH's new "shi" Li Song Yuqin and Zhang Huilai: Double-antibody Glofitamab helps T-cell immunotherapy start a new journey, and the unique administration method effectively improves the safety profile
Time of Update: 2022-02-24
Immunotherapy-induced CRS5 The current key clinical research safety data of CAR-T cell therapy compares Glofit's unique drug regimen to help reduce the incidence of CRS In the field of non-Hodgkin's lymphoma (NHL) treatment, in addition to CAR-T cell therapy, Another important research direction for T cell-mediated tumor therapy is bispecific antibodies, which can target two different antigen-binding sites: one for tumor antigens and the other for activating cytotoxic cells to exert anti-tumor activity .
-
Bleeding and thrombosis associated with CAR-T therapy
Time of Update: 2022-02-24
This article is from the NEJM Journal Watch Adverse Events Associated with CAR-T Therapy Review of Adverse Events Associated with CAR-T Therapy by Brady Stein, MD, MHS Bleeding or thrombosis occurs in some patients, especially those with older patients.
